IPP Bureau
Takeda seals $1.2 billion oncology deal with Innovent Biologics
By IPP Bureau - December 07, 2025
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Bayer advances fight against rare kidney disease with new experimental drug
By IPP Bureau - December 07, 2025
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Bayer launches phase III trial testing Mirena for uterine condition with no treatments
By IPP Bureau - December 07, 2025
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
Debiopharm launches pivotal phase III trial for novel quarterly acromegaly treatment
By IPP Bureau - December 07, 2025
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
Bayer reports promising results for low-dose pediatric MRI contrast agent
By IPP Bureau - December 07, 2025
MRI is particularly valuable in pediatric care due to its non-invasive nature
Biocon to merge Biocon Biologics in $5.5 billion deal
By IPP Bureau - December 07, 2025
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Clariant showcases VitiPure portfolio at CPHI India
By IPP Bureau - December 07, 2025
VitiPure serves as essential solubilizers, emulsifiers, and bioavailability enhancers in drug formulations
Merck Animal Health wins FDA’s fast-track green light for first-in-decades cattle parasite treatment
By IPP Bureau - December 06, 2025
The topical fluralaner solution is cleared for the prevention and treatment of new world screwworm infestation
Bristol Myers Squibb secures FDA nod for Breyanzi in marginal zone lymphoma
By IPP Bureau - December 06, 2025
The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
Briefs: IOL Chemicals & Pharmaceuticals, Ipca Laboratories and Anuh Pharma
By IPP Bureau - December 06, 2025
Ipca Laboratories receives three observations from USFDA for API facility at Tarapur
Lupin inks US licensing deal with Valorum for biosimilar Armlupeg
By IPP Bureau - December 05, 2025
Valorum will advance the commercialization and distribution of Armlupeg in the United States
Medtronic and Symbiosis International inaugurate center for advanced surgical, cadaver-based training
By IPP Bureau - December 05, 2025
The center will offer training to super-specialist doctors and healthcare professionals in various fields
Granules’ packaging facility in US completes FDA inspection with zero observations
By IPP Bureau - December 05, 2025
Granules Consumer Health serves as Granules’ front-end division for OTC products in the US
Fortis ropes in 'Yamraj' to launch nationwide helmet safety drive
By IPP Bureau - December 05, 2025
This campaign is to raise awareness about the crucial role helmet usage plays in saving lives
